These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 32256440)

  • 21. The influence of THC:CBD oromucosal spray on driving ability in patients with multiple sclerosis-related spasticity.
    Celius EG; Vila C
    Brain Behav; 2018 May; 8(5):e00962. PubMed ID: 29761015
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of nabiximols on Goal Attainment Scale scores in patients with treatment-resistant multiple sclerosis spasticity.
    Paul F; Silván CV
    Neurodegener Dis Manag; 2021 Apr; 11(2):143-153. PubMed ID: 33641348
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Nabiximols oromucosal spray in patients with multiple sclerosis-related bladder dysfunction: A prospective study.
    Torri Clerici V; Brambilla L; Politi PL; Viggiani F; Mercurio S; Tonietti S; Ronzoni M; Crisafulli SG; Antozzi C; Tramacere I; Redemagni C; Confalonieri P
    Mult Scler Relat Disord; 2023 Jun; 74():104711. PubMed ID: 37062198
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of Sativex on spasticity-associated symptoms in patients with multiple sclerosis.
    Meuth SG; Vila C; Dechant KL
    Expert Rev Neurother; 2015; 15(8):909-18. PubMed ID: 26166264
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A systematic review of European regional and national guidelines: a focus on the recommended use of nabiximols in the management of spasticity in multiple sclerosis.
    Carod-Artal FJ; Adjamian P; Vila Silván C; Bagul M; Gasperini C
    Expert Rev Neurother; 2022 Jun; 22(6):499-511. PubMed ID: 35582858
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-Term Data of Efficacy, Safety, and Tolerability in a Real-Life Setting of THC/CBD Oromucosal Spray-Treated Multiple Sclerosis Patients.
    Paolicelli D; Direnzo V; Manni A; D'Onghia M; Tortorella C; Zoccolella S; Di Lecce V; Iaffaldano A; Trojano M
    J Clin Pharmacol; 2016 Jul; 56(7):845-51. PubMed ID: 26608223
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of THC/CBD oromucosal spray on spasticity-related symptoms in people with multiple sclerosis: results from a retrospective multicenter study.
    Patti F; Chisari CG; Solaro C; Benedetti MD; Berra E; Bianco A; Bruno Bossio R; Buttari F; Castelli L; Cavalla P; Cerqua R; Costantino G; Gasperini C; Guareschi A; Ippolito D; Lanzillo R; Maniscalco GT; Matta M; Paolicelli D; Petrucci L; Pontecorvo S; Righini I; Russo M; Saccà F; Salamone G; Signoriello E; Spinicci G; Spitaleri D; Tavazzi E; Trotta M; Zaffaroni M; Zappia M;
    Neurol Sci; 2020 Oct; 41(10):2905-2913. PubMed ID: 32335779
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy of nabiximols oromucosal spray on spasticity in people with multiple sclerosis: Treatment effects on Spasticity Numeric Rating Scale, muscle spasm count, and spastic muscle tone in two randomized clinical trials.
    Nicholas J; Lublin F; Klineova S; Berwaerts J; Chinnapongse R; Checketts D; Javaid S; Steinerman JR
    Mult Scler Relat Disord; 2023 Jul; 75():104745. PubMed ID: 37209500
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The influence of physiotherapy intervention on patients with multiple sclerosis-related spasticity treated with nabiximols (THC:CBD oromucosal spray).
    Grimaldi AE; De Giglio L; Haggiag S; Bianco A; Cortese A; Crisafulli SG; Monteleone F; Marfia G; Prosperini L; Galgani S; Mirabella M; Centonze D; Pozzilli C; Castelli L
    PLoS One; 2019; 14(7):e0219670. PubMed ID: 31361750
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of the tolerability and efficacy of Sativex in multiple sclerosis.
    Moreno Torres I; Sanchez AJ; Garcia-Merino A
    Expert Rev Neurother; 2014 Nov; 14(11):1243-50. PubMed ID: 25331416
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sativex
    Markovà J; Essner U; Akmaz B; Marinelli M; Trompke C; Lentschat A; Vila C
    Int J Neurosci; 2019 Feb; 129(2):119-128. PubMed ID: 29792372
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cannabinoid Effect and Safety in Spasticity Following Stroke: A Double-Blind Randomized Placebo-Controlled Study.
    Marinelli L; Puce L; Mori L; Leandri M; Rosa GM; Currà A; Fattapposta F; Trompetto C
    Front Neurol; 2022; 13():892165. PubMed ID: 35812088
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Disease-Modifying Symptomatic Treatment (DMST) Potential of Cannabinoids in Patients with Multiple Sclerosis.
    Bruno A; Annovazzi P; Clerico M; Cocco E; Conte A; Marfia GA; Salvetti M; Tomassini V; Clerici VT; Totaro R; Dolcetti E; Centonze D
    Curr Neuropharmacol; 2024 Sep; ():. PubMed ID: 39279696
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical experience with THC:CBD oromucosal spray in patients with multiple sclerosis-related spasticity.
    Koehler J; Feneberg W; Meier M; Pöllmann W
    Int J Neurosci; 2014 Sep; 124(9):652-6. PubMed ID: 24392812
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Advances in the management of multiple sclerosis spasticity: experiences from recent studies and everyday clinical practice.
    Pozzilli C
    Expert Rev Neurother; 2013 Dec; 13(12 Suppl):49-54. PubMed ID: 24289844
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety and tolerability of nabiximols oromucosal spray: a review of real-world experience in observational studies, registries, and case reports.
    Prieto González JM; Vila Silván C
    Expert Rev Neurother; 2021 May; 21(5):547-558. PubMed ID: 33749480
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Practical tool to identify Spasticity-Plus Syndrome amongst patients with multiple sclerosis. Algorithm development based on a conjoint analysis.
    Fernández Fernández Ó; Costa-Frossard L; Martínez Ginés ML; Montero Escribano P; Prieto González JM; Ramió-Torrentà L; Aladro Y; Alonso Torres A; Álvarez Rodríguez E; Labiano-Fontcuberta A; Landete Pascual L; Miralles Martínez A; Moral Torres E; Oliva-Nacarino P
    Front Neurol; 2024; 15():1371644. PubMed ID: 38708001
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Review of Available Data for the Efficacy and Effectiveness of Nabiximols Oromucosal Spray (Sativex®) in Multiple Sclerosis Patients with Moderate to Severe Spasticity.
    Conte A; Vila Silván C
    Neurodegener Dis; 2021; 21(3-4):55-62. PubMed ID: 34731865
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Health Authorities Data Collection of THC:CBD Oromucosal Spray (L'Agenzia Italiana del Farmaco Web Registry): Figures after 1.5 Years.
    Patti F
    Eur Neurol; 2016; 75 Suppl 1():9-12. PubMed ID: 26901344
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sativex® (nabiximols) cannabinoid oromucosal spray in patients with resistant multiple sclerosis spasticity: the Belgian experience.
    D'hooghe M; Willekens B; Delvaux V; D'haeseleer M; Guillaume D; Laureys G; Nagels G; Vanderdonckt P; Van Pesch V; Popescu V
    BMC Neurol; 2021 Jun; 21(1):227. PubMed ID: 34157999
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.